Program
BI 3032950
A development code. Also written as “BI 3032950 intravenous (Part A)” and “BI 3032950 subcutaneous (Part B)”.
In Boehringer Ingelheim's pipeline, TREM-1 antagonist
. Its studies are mostly in Colitis, Ulcerative, led by Boehringer Ingelheim.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 31 open or running | phase 2since Oct 7, 2024 | Aug 25, 2022 | Jul 30, 2027phase 2 · NCT06636656 |
- Named in Boehringer Ingelheim’s own pipeline as
BI 3032950
, phase 2, as of Aug 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 25, 2022First study: phase 1 study in HealthyFirst studyNCT05518708 · 94 enrolled · Belgium
- Aug 3, 2023Phase 1 study in HealthyNCT05985200 · 40 enrolled · Belgium
- Oct 7, 2024Phase 2 study in Colitis, UlcerativeNCT06636656 · 80 planned · United States, Belgium, Czechia and more
Ahead
- Jul 30, 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT06636656
TargetBeta
“TREM-1 antagonist”the company's pipeline, read by Claude · source
Other programs on TREM1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ABBV-8736 | AbbVie | phase 2 | 3 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06636656Colitis, Ulcerative · United States, Belgium, Czechia and more | 2 | Recruiting | Jul 30, 2027 | 80 |
| NCT05985200Healthy · Belgium | 1 | Completed | Aug 19, 2024 | 40 |
| NCT05518708Healthy · Belgium | 1 | Completed | Sep 21, 2023 | 94 |
How it is read
Names in the registry
- “BI 3032950”, 2 entries
- “BI 3032950 intravenous (Part A)”, 1 entry
- “BI 3032950 subcutaneous (Part B)”, 1 entry
Codes read as this program: BI3032950.
Conditions, from the studies’ own filings
- Colitis, Ulcerative, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.